

In drug development, Phase II is the critical bridge that validates concepts and assesses efficacy. Its success is never accidental; it is deeply rooted in a rigorous data chain from preclinical stages through Phase I, and fundamentally dependent on high-purity, highly consistent research materials — an area where partners like Humanpro specialize in supporting translational and early clinical research.
Lire la suite →
After months of inaction from the U.S. Food and Drug Administration (FDA), the Natural Products Association (NPA) has officially filed a lawsuit challenging the FDA’s position on β-Nicotinamide Mononucleotide (NMN) — a popular dietary supplement ingredient known as a direct precursor of NAD⁺.
Lire la suite →Affichage de 19 - 20 sur 20 éléments